Share

Pharmacokinetics of the doxorubicin magnetic nanoconjugate in mice. Effects of the nonuniform stationary magnetic field.

O M Mykhaylyk, N O Dudchenko, A K Dudchenko

PAPERpubmedUkrains'kyi biokhimichnyi zhurnal (1999 )2005Animal studyEffect: mixedEvidence: Low

Abstract

Pharmacokinetics of the doxorubicin (DOX) conjugates with magnetite nanoparticles of the core/ shell type in mice following i.v. injection in a dose of 12.5 microg Fe/g tissue w/w was studied using electron spin resonance technique (ESR). Conjugation of the DOX with magnetic nanoparticles was shown to considerably decrease DOX bioavailability in the heart and kidney tissues compared to the free DOX. A non-uniform stationary magnetic field B of 210 mT and [deltaB] of 200 mT/cm was found to be efficient in increasing DOX conjugate bioavailability in the target site. The magnetic field was also found to inhibit conjugate accumulation in the liver resulted in the increased bioavailability of the conjugates in the blood. The phenomenon can be associated with in vivo inhibition of the phagocytic activity of the immunocompetent cells upon application of magnetic fields. Morphometry data in agreement with pharmacokinetic data revealed a decrease in the conjugate concentration in the liver tissue and cells as well as the relative decrease in conjugate concentration in the Kupffer cells compared to hepatocytes upon application of magnetic fields.

AI evidence extraction

At a glance
Study type
Animal study
Effect direction
mixed
Population
Mice
Sample size
—
Exposure
static magnetic field
Evidence strength
Low
Confidence: 74% · Peer-reviewed: yes

Main findings

After i.v. injection, conjugation of doxorubicin with magnetite nanoparticles decreased DOX bioavailability in heart and kidney compared with free DOX. Application of a non-uniform stationary magnetic field (B 210 mT; gradient 200 mT/cm) increased DOX conjugate bioavailability at the target site and inhibited conjugate accumulation in the liver, with increased bioavailability in blood. Morphometry findings were reported to align with pharmacokinetic results, showing decreased conjugate concentration in liver tissue/cells and relatively decreased concentration in Kupffer cells compared with hepatocytes under magnetic field application.

Outcomes measured

  • Pharmacokinetics/bioavailability of doxorubicin (DOX) magnetite nanoparticle conjugates in tissues (heart
  • kidney
  • liver
  • blood
  • target site)
  • Conjugate accumulation in liver
  • Morphometry of liver cells (Kupffer cells vs hepatocytes)

Limitations

  • Sample size not reported in abstract
  • Exposure duration/timing relative to injection not reported in abstract
  • Outcomes focused on drug distribution rather than health endpoints
  • Mechanistic explanation (phagocytic inhibition) is suggested but not directly established in the abstract
View raw extracted JSON
{
  "study_type": "animal",
  "exposure": {
    "band": null,
    "source": "static magnetic field",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": null
  },
  "population": "Mice",
  "sample_size": null,
  "outcomes": [
    "Pharmacokinetics/bioavailability of doxorubicin (DOX) magnetite nanoparticle conjugates in tissues (heart, kidney, liver, blood, target site)",
    "Conjugate accumulation in liver",
    "Morphometry of liver cells (Kupffer cells vs hepatocytes)"
  ],
  "main_findings": "After i.v. injection, conjugation of doxorubicin with magnetite nanoparticles decreased DOX bioavailability in heart and kidney compared with free DOX. Application of a non-uniform stationary magnetic field (B 210 mT; gradient 200 mT/cm) increased DOX conjugate bioavailability at the target site and inhibited conjugate accumulation in the liver, with increased bioavailability in blood. Morphometry findings were reported to align with pharmacokinetic results, showing decreased conjugate concentration in liver tissue/cells and relatively decreased concentration in Kupffer cells compared with hepatocytes under magnetic field application.",
  "effect_direction": "mixed",
  "limitations": [
    "Sample size not reported in abstract",
    "Exposure duration/timing relative to injection not reported in abstract",
    "Outcomes focused on drug distribution rather than health endpoints",
    "Mechanistic explanation (phagocytic inhibition) is suggested but not directly established in the abstract"
  ],
  "evidence_strength": "low",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "doxorubicin",
    "magnetite nanoparticles",
    "magnetic nanoconjugate",
    "pharmacokinetics",
    "electron spin resonance",
    "static magnetic field",
    "non-uniform magnetic field",
    "bioavailability",
    "liver",
    "Kupffer cells"
  ],
  "suggested_hubs": [
    {
      "slug": "static-magnetic-fields",
      "weight": 0.9,
      "reason": "Study applies a non-uniform stationary (static) magnetic field (210 mT; 200 mT/cm) in vivo."
    }
  ]
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.

NNEMF synthesis

Synthesis pending.

Original record: rfsafe.org paper 3579

Pharmacokinetics of the doxorubicin magnetic nanoconjugate in mice. Effects of the nonuniform stationary magnetic field. · Non-native EMF